TRDA — Entrada Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $288.07m
- -$94.45m
- $210.78m
- 65
- 95
- 34
- 71
Annual income statement for Entrada Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 129 | 211 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 26.7 | 51.1 | 97.2 | 132 | 164 |
| Operating Profit | -26.7 | -51.1 | -97.2 | -3.16 | 47 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -26.5 | -51.2 | -94.6 | 12.1 | 66.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -26.5 | -51.2 | -94.6 | -6.68 | 65.6 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -26.5 | -51.2 | -94.6 | -6.68 | 65.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -26.5 | -51.2 | -94.6 | -6.68 | 65.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.887 | -8.16 | -3.02 | -0.202 | 1.68 |
| Dividends per Share |